索拉非尼联合胸腺肽α1治疗晚期肝癌疗效

Efficacy of sorafenib with thymosin α1 for patients with advanced hepatocellular carcinoma

目的评价索拉非尼联合胸腺肽α1治疗晚期肝细胞肝癌(HCC)的疗效。方法 40例晚期HCC患者随机均分两组:A组口服索拉非尼(400mg,2次/d);B组加用胸腺肽α1(1.6mg,2次/周)。每4周为一周期。三周期后评估疗效(RECIST标准)和毒性反应(NCI-CTC标准)。结果 B组疾病控制率(DCR)、中位肿瘤进展时间(mTTP)、中位总生存期(mOS)、CD3+、CD4+、CD8+、CD4+/CD8+、CD8+/CD28+、CD16+/CD56+均明显高于A组(P<0.05)。结论索拉非尼联合胸腺肽α1治疗晚期HCC能明显提高患者的免疫功能。

Objective To evaluate the efficacy of sorafenib combined with thymosin α1in the patients with advanced hepatocellular carcinoma（HCC）.Methods Fourty patients with HCC were randomly divided into two groups with 20 cases each.Group A was treated by sorafenib 400mg,bid alone and group B treated with additional thymosin α1 1.6mg twice a week.The outcomes were evaluated with RECIST and NCI-CTC criteria every 12 weeks.Results The total disease control rate,median TTP,median survival time and the expressions of CD3＋,CD4＋,CD8＋,and the ratios of CD4＋/CD8＋,CD8＋/CD28＋ and CD16＋/CD56＋ were higher in group B than those in group A（P0.05）.Conclusion Treating with sorafenib combined with thymosin α1 can effectively improve the immunity in the patients with HCC.